Twist Bioscience (NASDAQ:TWST) CEO Sells $147,396.16 in Stock

Posted by Brian Himes on Jun 24th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CEO Emily Leproust sold 1,688 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total value of $147,396.16. Following the sale, the chief executive officer owned 842,919 shares of the company’s stock, valued at approximately $73,603,687.08. The trade was a 0.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Trading Up 7.5%

Shares of TWST traded up $6.35 during trading hours on Wednesday, hitting $91.35. The stock had a trading volume of 2,440,109 shares, compared to its average volume of 1,477,205. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $93.80. The firm has a market cap of $5.69 billion, a P/E ratio of -68.68 and a beta of 2.23. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. The company’s fifty day simple moving average is $64.56 and its 200 day simple moving average is $50.23.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million for the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. Twist Bioscience’s revenue was up 19.3% on a year-over-year basis. During the same period last year, the firm posted ($0.66) EPS. Equities research analysts forecast that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. UBS Group set a $89.00 price target on shares of Twist Bioscience in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Leerink Partners set a $80.00 price objective on shares of Twist Bioscience in a research report on Friday, May 22nd. Canaccord Genuity Group started coverage on shares of Twist Bioscience in a research note on Monday, June 15th. They issued a “buy” rating and a $90.00 target price on the stock. Finally, Robert W. Baird lifted their target price on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $74.60.

Read Our Latest Stock Analysis on TWST

Institutional Trading of Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. EdgePoint Investment Group Inc. grew its holdings in Twist Bioscience by 71.1% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after purchasing an additional 1,696,377 shares in the last quarter. First Light Asset Management LLC lifted its holdings in Twist Bioscience by 26.4% in the 3rd quarter. First Light Asset Management LLC now owns 1,194,883 shares of the company’s stock worth $33,624,000 after buying an additional 249,850 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Twist Bioscience by 350.3% in the 4th quarter. SG Americas Securities LLC now owns 76,484 shares of the company’s stock worth $2,426,000 after buying an additional 59,500 shares in the last quarter. William Blair Investment Management LLC boosted its position in Twist Bioscience by 6.0% in the 3rd quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock valued at $116,564,000 after buying an additional 235,679 shares during the last quarter. Finally, Rafferty Asset Management LLC grew its stake in shares of Twist Bioscience by 51.0% during the third quarter. Rafferty Asset Management LLC now owns 114,268 shares of the company’s stock valued at $3,216,000 after acquiring an additional 38,608 shares in the last quarter.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.